Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

17Citations
Citations of this article
49Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Widespread use of ten-valent (Synflorix™, GSK) or 13-valent (Prevenar 13™; Pfizer) conjugate vaccination programs has effectively reduced invasive pneumococcal disease (IPD) globally. However, IPD caused by serotypes not contained within the respective vaccines continues to increase, notably serotypes 3, 6A, and 19A in countries using lower-valent vaccines. Our objective was to estimate the clinical and economic benefit of replacing PCV10 with PCV13 in Colombia, Finland, and The Netherlands. Methods: Country-specific databases, supplemented with published and unpublished data, informed the historical incidence of pneumococcal disease as well as direct and indirect medical costs. A decision-analytic forecasting model was applied, and both costs and outcomes were discounted. The observed invasive pneumococcal disease (IPD) trends from each country were used to forecast the future number of IPD cases given a PCV13 or PCV10 program. Results: Over a 5-year time horizon, a switch to a PCV13 program was estimated to reduce overall IPD among 0–2 year olds by an incremental − 37.6% in Colombia, − 32.9% in Finland, and − 26% in The Netherlands, respectively, over PCV10. Adults > 65 years experienced a comparable incremental decrease in overall IPD in Colombia (− 32.2%), Finland (− 15%), and The Netherlands (− 3.7%). Serotypes 3, 6A, and 19A drove the incremental decrease in disease for PCV13 over PCV10 in both age groups. A PCV13 program was dominant in Colombia and Finland and cost-effective in The Netherlands at 1 × GDP per capita (€34,054/QALY). Conclusion: In Colombia, Finland, and The Netherlands, countries with diverse epidemiologic and population distributions, switching from a PCV10 to PCV13 program would significantly reduce the burden of IPD in all three countries in as few as 5 years.

References Powered by Scopus

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

1179Citations
N/AReaders
Get full text

Serotype replacement in disease after pneumococcal vaccination

762Citations
N/AReaders
Get full text

Dexamethasone as adjunctive therapy in bacterial meningitis: A meta- analysis of randomized clinical trials since 1988

392Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies

15Citations
N/AReaders
Get full text

Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands

11Citations
N/AReaders
Get full text

Cost-Effectiveness Analysis of the South African Infant National Immunization Program for the Prevention of Pneumococcal Disease

10Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Pugh, S., Wasserman, M., Moffatt, M., Marques, S., Reyes, J. M., Prieto, V. A., … Farkouh, R. (2020). Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis. Infectious Diseases and Therapy, 9(2), 305–324. https://doi.org/10.1007/s40121-020-00287-5

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

67%

Researcher 5

24%

Professor / Associate Prof. 1

5%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

47%

Pharmacology, Toxicology and Pharmaceut... 3

20%

Nursing and Health Professions 3

20%

Social Sciences 2

13%

Save time finding and organizing research with Mendeley

Sign up for free